Home
    Webcasting
    Registration
    Accommodation
    Contact
     Home
     Scientific Committee
     Welcome Note
     Topics
     Faculty
     Satellite Symposia
         Webcasting
     Timetable & Program
         Friday, February 6, 2009
         Saturday, February 7, 2009
         Sunday, February 8, 2009
     Poster Presentation Schedule
         Group A
         Group B
         Poster Presentation Guidelines
         E-Posters
     Congress Prize
         Awardees
     CME
     Registration
     Invitation Letter
     Accommodation
     Accompanying Persons Program
     Sponsorship & Exhibition
     Sponsors
     General Information
         Before you travel ...
     Official Airline Network
     Italian Agent
     Contact Us
The 2nd World Congress on
Controversies in Urology (CURy)
Lisbon, Portugal, February 5- 8, 2009
 
  Topics Print
Prostate Cancer: Diagnosis
 
  • Are new markers useful in clinical practice?
  • PSA thresholds for biopsy
  • Is PSA Velocity selective for clinically significant CaP?
  • Nomograms and predicting tables: Pros and cons
  • MRI of the Prostate: does it dictate treatment?
  • Obesity and Prostate cancer: a mist or a threat?
 
Prostate Cancer: Localized Disease
 
Which treatment is best for clinically localized-prostate cancer?

§         Active surveillance

§         Surgery

§         Brachytherapy

§         Radiation therapy and hormones

§         Image guided focal therapy

 
Prostate Cancer: Locally Advanced Disease 
  •  Is there a place for surgery?
  • Positive margins: To treat or not to treat?
  • The role of chemotherapy in locally advanced disease
  • Bladder cancer risk following radiation for Prostate Cancer
 
Prostate Cancer: Hormonal Treatment
  • Optimizing therapy in advanced and metastatic prostate cancer Continuous vs. intermittent therapy?
  • Are all hormonal treatments similar?
  • Anti-androgen monotherapy: Is it still recommended?
  • Are LH-RH Antogonists of significant advantage?
 
Prostate Cancer: Metastatic Disease and Hormone Refractory Prostate Cancer (HRPC)
 
  • Metastatic disease: Early vs. delayed treatment
  • The role of chemotherapy
  • The role of bisphosphates
  • Targeted therapies: when and for whom?
 
Bladder Cancer: Non muscle invasive disease
 
  • Are new diagnostic markers useful?
  • Low-grade tumors: surveillance rather than treatment?
  • High-grade tumors: How should they be treated?
  • BCG: Optimizing efficacy and managing toxicity
  • Mitomycin C: enhancing activity
  • Is maintenance therapy indicated for CIS?
 
Bladder Cancer: Muscle Invasive Tumors
 
  • Bladder preservation: Pros and cons
  • Elderly patients: What is the best treatment?
  • Neoadjuvant vs. adjuvant chemotherapy: Are these treatments beneficial?
  • Urinary diversion: Options, patient selection and outcomes
  • Bladder substitution: Standard or exception?
  • Metastatic disease: Is there any effective treatment?
  • Potential targets for novel treatment
 
Upper Tract TCC 
 
  • Can the kidney be preserved?
  • Open vs. Laparoscopic Nephroureterectomy: Pros and cons
  • Neoadjuvant and adjuvant treatment
BPH
 
  • Does the clinical practice of BPH treatment differ from that of guidelines?
  • Who needs treatment? What do we treat?
  • What should be the primary treatment?
  • Phytotherapy: Pros and cons
  • Combination therapy vs. single treatment
  • Laser surgery vs. standard surgery
  • Saline vaporization vs. laser vaporization
 
Testosterone Deficiency
 
  • Testosterone treatment: For whom?
  • Testosterone and the Prostate
  • Testosterone and Metabolic Syndrome
  • Testosterone and Sexual Function
 
Overactive bladder
 
  • What do we treat?
  • Who do we treat?
  • How do we treat?
  • What drugs?
  • Botulinum toxin and desensitization: Pros and cons
 
Incontinence
 
  • Injectables: Pros and cons
  • Tapes and slings: Which approach? Which material?
  • Pelvic prolapse: Best management?
  • Post-prostatectomy incontinence: Which approach?
 
Erectile Dysfunction
 
  • ED: a symptom or a clinical condition?
  • Erectile dysfunction: Is there a best drug?
  • PDI5 inhibitors: How to determine treatment failure?
  • Testosterone and PDI5: When and for whom?
  • ED post-prostatectomy: What is the ideal management?
  • LUTS and ED: Coincidence or association?
  • Ejaculatory disorders: best management
  • Peyronie's Disease
 
EndoUrology and Urolithiasis
 
  • Upper ureteric stones: What is the best treatment?
  • Lower ureteral stones: ureteroscopy vs ESWL
  • ESWL – What is new?
  • Determining the ESWL's treatment endpoint
  • Long term adverse effects of ESWL and PCNL
  • UPJ obstruction: Endopyelotomy vs pyeloplasty (Lap or open)
  • Lower pole kidney stone: ESWL vs. RIRS vs. WW
 

SURGICAL TIPS AND TEACHING VIDEOS

Home    Scientific Committee    Abstracts    Registration     Accommodation     Sponsorship & Exhibition    General Information    Contact Us   
Copyright © 2007 comtecmed.com. All rights reserved. Created by     WebStudio.co.il